Chronic Constipation in the Elderly Patient: Updates in Evaluation and Management

Amir Mari¹,²*, Mahmud Mahamid¹,², Hana Amara¹,², Fadi Abu Baker³, Afif Yaccob⁴

¹Gastroenterology Institute, Nazareth EMMS Hospital, Nazareth, Israel
²The Azrieli Faculty of Medicine, Bar-Ilan University, Ramat Gan, Israel
³Gastroenterology Institute, Hillel Yaffe Medical Center, Rappaport Faculty of Medicine, Haifa, Israel
⁴Gastroenterology and Liver Disease Department, Rambam Healthcare Campus, Haifa, Israel

Chronic constipation (CC) is a common disorder in the elderly population globally and is associated with comorbidities and negative implications on the quality of life. Constipation prevalence varies in different studies, primarily owing to the nonuniformity of the diagnostic criteria. However, 15%–30% of individuals aged >60 years are diagnosed with CC. Primary care physicians are the main healthcare providers that manage constipation in elderly patients in parallel with increased population aging and increased prevalence of constipation. Physical inactivity, polypharmacy, chronic medical conditions, rectal hyposensitivity, and defecatory disorders all play a role in the pathogenesis of CC in elderly patients. Detailed anamnesis, particularly history related to chronic medication use, with digital rectal examination may assist in identifying constipation causes. Additionally, blood tests and colonoscopy may identify organic causes of CC. Physiologic tests (i.e., anorectal manometry, colonic transit time with radiopaque markers, and defecography) can evaluate the physiologic function of the colon, rectum, and anus. However, generally, there are several causes of constipation in older patients, and an individualized approach is recommended. Treatment of chronic idiopathic constipation is empiric, based on the stepwise approach. Lifestyle advice, adjustment of chronic medications, and prescription of laxatives are the first steps of management. Several laxatives are available, and the treatment is evolving in the last decade. Biofeedback is an effective therapy especially for defecatory disorders. This review aimed to summarize the most updated knowledge for primary care physicians in the approach and management of CC in elderly patients.

Keywords: Chronic Constipation; Approach; Elderly; Treatment; Management; Primary Care Physicians

Received: October 17, 2018, Revised: December 9, 2018, Accepted: December 19, 2018

*Corresponding Author: Amir Mari
https://orcid.org/0000-0002-6828-4738
Tel: +972-54-214-2070, Fax: +972-4-6028844, E-mail: amir_mari@nazhosp.com

Copyright © 2020 The Korean Academy of Family Medicine
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION

The prevalence of chronic constipation (CC) increases with age in both sexes, particularly above the age of 60 years. In two related global surveys, the prevalence of self-defined constipation in Asian adults (from South Korea, China, and Indonesia) was estimated to be 15%–23% in women and approximately 11% in men. CC leads to major impairments in the quality of life and is an economic burden to the patient and national health services. The definition of CC between patients and physicians and among different physicians lacks uniformity; thus, the reported prevalence is diverse in different epidemiological studies. An international expert committee congregated in 2016 in Rome to update the definition of CC (Rome IV criteria) (Table 1). The most prevalent complaints in elderly patients with constipation are as follows: need to apply prolonged abdominal pressure during defecation, sensation of outlet obstruction at the level of the anus, and digitalization to relieve impacted stool. The main risk factors for constipation in the elderly population include the following: immobility, weakness of the abdominal and pelvic floor muscles, malnutrition, rectal hyposensitivity, ignoring a “defecation call,” chronic medical conditions (metabolic, neurologic, cardiovascular), chronic medication use (analgesics, calcium channel blockers, antihypertensive drugs, and antipsychotics), and aging effects on colonic motility (Tables 2, 3). Additionally, psychological, social, and behavioral factors may contribute to the development of CC in the elderly population. CC may lead to serious anorectal complications, including anal pain, anal fissures, hemorrhoids, rectal bleeding, and fecal impaction, a stern condition that may cause restlessness, anxiety, rectal ulcers, and perforation in extremely rare cases.

CLASSIFICATION OF PRIMARY CHRONIC CONSTIPATION

1. Slow Transit Constipation

It is a type of constipation in the elderly population and characterized by infrequent bowel movements and slow movement of stool through the colon. Patients with slow transit constipation often have reduced frequency of high-amplitude propagated contractions (the physiological function of moving contents through the colon) after meals. Bloating, abdominal pain, and an infrequent urge to defecate are commonly associated with this condition clinically. Histopathological studies have shown several processes such as myopathic and degenerative alterations in the colonic smooth muscle cells and collagen depositions in the right colon to lead to colonic hypomotility in elderly patients with constipation.

2. Normal Transit Constipation

Normal transit constipation is characterized by a normal rate of stool movement through the colon, but the patient feels constipated. This is usually secondary to perceived difficulty with defecation and hard stools. Patients often complain of bloating and abdominal pain. At other times, these patients present with abdominal pain, which is relieved by defecation, and therefore the symptoms may overlap those of constipation-predominant irritable bowel syndrome (IBS).

3. Defecatory Disorders

Defecatory disorders are most commonly due to functional paradoxical contraction of the pelvic floor, abdominal muscles, and anal sphincter (dysssenergia or anismus) and are the type of constipation in the elderly population. Patients typically report an inability to defe-

Table 1. Rome IV criteria for primary chronic constipation

| Rome IV criteria                |
|---------------------------------|
| (1) Must include 2 or more of the following: |
| - Straining in >25% of defecations |
| - Lumpiness or hard stools in >25% of defecations |
| - Sensation of incomplete evacuation in >25% of defecations |
| - Sensation of anorectal obstruction/blockage in >25% of defecations |
| - Manual maneuvers to facilitate >25% of defecations (e.g., digital evacuation and support of the pelvic floor) |
| - Fewer than 3 spontaneous bowel movements per week |
| (2) Loose stools are rarely present without the use of laxatives |
| (3) Insufficient criteria for irritable bowel syndrome |

Criteria fulfilled for the last 3 months with symptom onset at least 6 months prior to diagnosis.

Table 2. Risk factors of chronic constipation in elderly patients

| Risk factors                      |
|-----------------------------------|
| (1) Immobility or sedentary lifestyle |
| (2) Weakness of the abdominal and pelvic floor muscles |
| (3) Malnutrition or low-fiber diet |
| (4) Ignoring a defecation call |
| (5) Rectal hyposensitivity |
| (6) Chronic medical conditions |
| - Metabolic (diabetes mellitus, chronic kidney failure, electrolyte disturbances, hypothyroidism) |
| - Neurologic (Parkinson’s disease, multiple sclerosis, spinal cord lesions, and cerebrovascular accidents) |
| - Cardiovascular (ischemic heart diseases, congestive heart diseases) |
| (7) Cancer-related causes |
| (8) Aging effects on colonic motility |
| (9) Psychological, social, and behavioral factors |

Table 3. Medications causing constipation

| Medications                  |
|------------------------------|
| Opioids                      |
| Calcium channel blockers     |
| Diuretics                    |
| Antipsychotics               |
| Iron supplements             |
| Nonsteroidal anti-inflammatory drugs |
| Calcium supplements          |
| Antiparkinson drugs          |
| Anticholinergic drugs        |
| Proton pump inhibitors       |
| Anticonvulsants              |
EVALUATION AND DIAGNOSIS

The primary aim of evaluation is to rule out secondary or organic cause of constipation that may be treated differently depending on the specific pathology. A detailed medical history with a focus on alarm signs (i.e., rectal bleeding, weight loss, personnel or family history of colon cancer, new iron deficiency anemia, and changes in bowel habits) (Table 4), chronic medical condition use, medication history, and social history is the first important step in managing an elderly patient with constipation. Examination of the perianal area for suggestive findings of CC, such as scars, fistulas, anal fissures, skin erythema or excoriation (may be a sign of fecal leakage), and external hemorrhoid, is an important initial part of the evaluation. Rectal examination is essential in identifying internal hemorrhoids, rectal prolapse, rectocele, fecal impaction, anal stricture, and rectal masses and aids in the diagnosis of functional defecatory disorders. Blood tests, including blood count, blood glucose level, liver and kidney function tests, electrolyte level, thyroid function tests, and inflammatory markers, are necessary to exclude a secondary cause of constipation, albeit their yield is generally low and the chance to detect an abnormality showing constipation is unlikely. A Korean study aimed to determine the utility of blood tests, including blood count, blood glucose level, liver and kidney function tests, electrolyte level, thyroid function tests, and inflammatory markers. Retention of >20% of the markers after 120 hours is considered a pathological result and an indicator of slow transit constipation.

1. Evacuation Proctography
This is a technique that evaluates anorectal morphology and dynamics during defection. It is used to determine whether complete emptying of the rectum is achieved and measure the anorectal angle and perianal descent. It can be used to detect other abnormalities of rectal emptying, such as intussusception, mucosal prolapse, solitary rectal ulcer, and rectocele.

2. Radiopaque Marker
It is a technique that measures colonic transit time, and is a useful, practical measure of the motor function. Transit time can be measured by performing abdominal radiography after ingestion of radiopaque markers. Retention of >20% of the markers after 120 hours is considered a pathological result and an indicator of slow transit constipation.

3. Anorectal Manometry
It provides important information on anorectal sensory and motor functions, anal sphincter resting and contraction pressures, and anorectal reflexes and can diagnose functional defecatory disorders (anismus).

4. Wireless Motility Capsule
Wireless Motility Capsule (WMC) is a novel technology introduced to the clinical practice in the last decade that assesses gut motility. WMC measures intraluminal temperature, pH, and pressure in different segments of the gastrointestinal (GI) tract and can measure regional or whole GI transit times. WMC is noninvasive, safe, and well tolerated by patients. However, presently, WMC is not used as a routine clinical investigation; rather, it is a research investigation tool whose clinical utility, value, and accuracy have not yet been entirely validated.

PREVENTION AND MANAGEMENT

1. Dietary and Lifestyle Advice
Elderly patients with mild constipation benefit from changes to their diet and lifestyle. Excluding patients with symptoms of dehydration, there is no evidence that increasing water intake alone increases stool frequency and softens consistency. Dietary fiber increases stool bulk...
and frequency, and some patients with low dietary fiber intake may benefit from a moderate increase in intake to 25–30 g. Dietary fibers are unlikely to have any benefit in severe constipation, especially in patients with slow transit or evacuation disorders. Dietary fibers may aggravate symptoms of abdominal bloating and flatulence; therefore, it is important to commence dietary fibers in the lowest possible dose, generally 5 g, and increase the amount gradually up to 25–30 g with adequate water intake. Studies have shown that increased moderate physical activity in elderly patients is associated with improvement in mild constipation symptoms but is unlikely to have an effect in patients with severe constipation. Furthermore, studies have shown that immobility in an elderly patient worsens the symptoms of constipation and is considered a risk factor for fecal impaction.

2. Drug Withdrawal
It is crucial to revise the medication list and attempt to stop any drug that may cause constipation, if possible.

3. Toileting Education
It is important to advise patients to employ correct toileting routines, such as regular, unhurried defecation, responding immediately to the sensation of needing to defecate (defecation call), having appropriate assistance to access the toilet, and avoiding prolonged pushing.

4. Laxatives
Laxatives are generally required for the management of constipation in the elderly population in case of inability to achieve symptom relief through lifestyle and dietary modifications (Figure 1). The choice of drug to be prescribed should be personalized for each patient, taking into account the patient’s medical history, medications, kidney and liver function test results, and electrolyte status. In this review, we will focus on the most commonly used laxatives in daily clinical practice.

1) Osmotic laxatives
These are laxatives that apply osmotic pressure within the colon lumen, thus attracting water and electrolytes and causing increased intraluminal pressure and volume. Osmotic laxatives cause stool softening, shorten colonic transit time, and enhance colonic motility. The use of insoluble sugars, such as lactulose and macrogel, has been shown to be safe and effective in elderly patients, and starting lactulose 15 g/d is a reasonable early pharmacological option in managing CC in elderly patients. Another important group of osmotic laxatives are polyethylene glycol (PEG)-based formulations. PEG-based formulations were originally used for colon cleansing before colonoscopy. However, they have also been shown to be useful in fecal disimpaction in the elderly population. PEG-based formulations are currently used in a form of powder for the management of CC starting with a daily dose of 17 g, which may be increased gradually if needed and tolerated by the patient. These drugs are generally effective and safe for use in the elderly. Some PEG-based formulations contain sodium and potassium; it is unknown whether small quantities may lead to electrolyte disturbances in elderly patient and should be avoided.

2) Stimulant laxatives
Bisacodyl and sodium picosulfate are the best known and most studied stimulant laxatives. Two recent randomized clinical trials on adults, using both picosulfate and bisacodyl at an average dose of 10 mg daily, involving a total of 735 primary care patients, have been shown to relieve symptoms of constipation and improve quality of life. Nonetheless, high-quality, randomized control trials that aimed to evaluate the efficacy and safety of stimulant laxatives in the elderly population are limited. However, based on the extensive experience with bisacodyl and sodium picosulfate and the known safety and efficacy, they may be added to osmotic laxatives in the lowest possible dose (5 mg), in ad hoc bases up to 2–3 times a week, while monitoring the clinical status of the patient and electrolyte and kidney function test results. Despite the common use of senna, there is actually no well-designed randomized controlled trial comparing its efficacy with placebo.

5. Suppositories and Enema
Suppositories and enemas may be used in elderly patients with immobility to enhance defecation and prevent stool impaction. Phosphate-based enemas are not recommended in elderly patients due to the risk of hyperphosphatemia; thus, water-based enemas are the preferred form.

---

**Figure 1. Management algorithm in the elderly patient with chronic constipation.**

- PEG, polyethylene glycol.
6. Prokinetic Agents
Prucalopride is an enterokinetic agent that activates serotonergic receptors and leads to the release of acetylcholine and activation of the myenteric plexus, thus enhancing colonic motility. Prucalopride has been shown to shorten bowel transit time, relieve constipation symptoms, and improve the quality of life mainly in women in clinical trials. Prucalopride has been shown to be effective and safe in the Asian population in a randomized, double blinded, placebo controlled trial. Prucalopride has high selectivity for the 5-hydroxytryptamine 4 receptor with extremely encouraging safety and tolerability profiles; hence, it has been approved in some countries for use in the elderly population. Prucalopride 2 mg is prescribed when other laxatives have failed to control the symptoms of constipation.

7. Lubiprostone
It is a secretory drug (chloride channel activator) acts locally to increase intestinal fluid secretion and improve colonic transit. It has been shown to be more effective than placebo in increasing the number of spontaneous bowel movements, decreasing straining, improving stool consistency, and relieving symptoms of CC. Lubiprostone has been shown to be effective for relief of IBS symptoms at a low dose of 8 μg and effective and safe for relief CC symptoms and opioid-induced constipation in non-oncological patients. Lubiprostone has been shown to be safe in elderly patients; however, studies have a small number of participants.

8. Biofeedback
Biofeedback is a training practice that aims to educate patients to relax, instead of contracting their pelvic floor muscles and abdominal muscles during straining, with the aid of visual or auditory signals to feedback patient’s performance. Currently, biofeedback therapy is useful mainly to patients with pelvic floor dyssynergia (anismus). Generally, biofeedback is an effective and safe treatment with a reported success rate of 70%–80% after 1 year. In the Asian, including Korean, population, biofeedback success rates are comparable to those in the Western population. Nonetheless, biofeedback trials in elderly patients are limited, and the decision should be personalized for each patient based in the cognitive and physical status and level of cooperation with the therapist.

Surgery
Surgery (colectomy with ileo-anal anastomosis) is not recommended in elderly patients due to high morbidity and mortality rates associated with major surgeries in frail elderly patients.

Conclusion
CC is a common medical condition in the elderly population and associated with distress and impairment of quality of life. The primary care physicians are the main providers that manage CC in the elderly population along with the global aging of the population. Dietary advice and lifestyle modifications are the primary interventions in the management algorithm. Osmotic laxatives are safe and efficient and should be the first-line therapy. Stimulant laxatives are added in the lowest effective dose when osmotic laxatives fail to achieve adequate relief. New drugs have been introduced to the armamentarium, such as prucalopride and lubiprostone, with promising results in adults; however, their efficacy and safety have been shown in elderly patients only in small sample studies. More randomized, controlled trials are warranted to better define the efficacy and safety of the new drugs in elderly patients.

Conflict of Interest
No potential conflict of interest relevant to this article was reported.

Orcid
Amir Mari: https://orcid.org/0000-0002-6828-4738
Mahmud Mahamid: https://orcid.org/0000-0001-5772-9052
Hana Amara: https://orcid.org/0000-0002-8914-8196
Fadi Abu Baker: https://orcid.org/0000-0001-5428-7180
Afif Yaccoh: https://orcid.org/0000-0003-3058-5583

References
1. Pare P, Ferrazzi S, Thompson WG, Irvine EJ, Rance L. An epidemiological survey of constipation in canada: definitions, rates, demographics, and predictors of health care seeking. Am J Gastroenterol 2001;96:3130-7.
2. Wald A, Scarpignato C, Mueller-Lissner S, Kamm MA, Hinkel U, Helfrich I, et al. A multinational survey of prevalence and patterns of laxative use among adults with self-defined constipation. Aliment Pharmacol Ther 2008;28:917-30.
3. Wald A, Mueller-Lissner S, Kamm MA, Hinkel U, Richter E, Schuit C, et al. Survey of laxative use by adults with self-defined constipation in South America and Asia: a comparison of six countries. Aliment Pharmacol Ther 2010;31:274-84.
4. Bouras EP, Tangalos EG. Chronic constipation in the elderly. Gastroenterol Clin North Am 2009;38:463-80.
5. Drossman DA, Hasler WL. Rome IV-functional GI disorders: disorders of gut-brain interaction. Gastroenterology 2016;150:1257-61.
6. Bernard CE, Gibbons SJ, Gomez-Pinilla PJ, Lukren MS, Schmalz PF, Roeder JL, et al. Effect of age on the enteric nervous system of the human colon. Neurogastroenterol Motil 2009;21:746-54.
7. Lajer E, Delvaux M, Vellas B, Fioramonti J, Bueno L, Albarede JL, et al. Influence of age on rectal tone and sensitivity to distension in healthy subjects. Neurogastroenterol Motil 1999;11:101-7.
8. Gallagher P, O’Mahony D. Constipation in old age. Best Pract Res Clin Gastroenterol 2009;23:875-87.
9. Camilleri M, Lee JS, Viramontes B, Bharucha AE, Tangalos EG. Insights into the pathophysiology and mechanisms of constipation, irritable bowel syndrome, and diverticulosis in older people. J Am Geriatr Soc

https://doi.org/10.4082/kjfm.18.0182
of the safety of Transipeg for treating constipation in community medicine. J Drug Assess 1999;2:97-108.
30. Chaussade S, Minic M. Comparison of efficacy and safety of two doses of two different polyethylene glycol-based laxatives in the treatment of constipation. Aliment Pharmacol Ther 2003;17:165-72.
31. Ford AC, Moayyedi P, Lacy BE, Lembo AI, Saito YA, Schiller LR, et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol 2014;109 Suppl 1:S2-26.
32. Mueller-Lissner S, Kamm MA, Wald A, Hinkel U, Koehler U, Richter E, et al. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of sodium picosulfate in patients with chronic constipation. Am J Gastroenterol 2010;105:897-903.
33. Kamm MA, Mueller-Lissner S, Wald A, Richter E, Swallow R, Gessner U. Oral bisacodyl is effective and well-tolerated in patients with chronic constipation. Clin Gastroenterol Hepatol 2011;9:577-83.
34. Rao SS, Go JT. Update on the management of constipation in the elderly: new treatment options. Clin Interv Aging 2010;5:163-71.
35. Muller-Lissner S, Rykx A, Kerstens R, Vandeplassche L. A double-blind, placebo-controlled study of prucalopride in elderly patients with chronic constipation. Neurogastroenterol Motil 2010;22:991-8.
36. Camilleri M, Pissevaux H, Yiannakou Y, Tack J, Kerstens R, Quigley EMM, et al. Efficacy and safety of prucalopride in chronic constipation: an integrated analysis of six randomized, controlled clinical trials. Dig Dis Sci 2016;61:2357-72.
37. Ke M, Zou D, Yuan Y, Li Y, Lin L, Hao J, et al. Prucalopride in the treatment of chronic constipation in patients from the Asia-Pacific region: a randomized, double-blind, placebo-controlled study. Neurogastroenterol Motil 2012;24:999-1009.
38. Chang L, Chey WD, Drossman D, Losch-Beridon T, Wang M, Lichtlen P, et al. Effects of baseline abdominal pain and bloating on response to lubiprostone in patients with irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2016;44:1114-22.
39. Webster LR, Brewer RP, Lichtlen P, Losch-Beridon T, Mareya S, Wang M. Efficacy of lubiprostone for the treatment of opioid-induced constipation, analyzed by opioid class. Pain Med 2018;19:1195-205.
40. Gras-Miralles B, Cremonini F. A critical appraisal of lubiprostone in the treatment of chronic constipation in the elderly. Clin Interv Aging 2015;8:191-200.
41. Chiarioni G, Heymen S, Whitehead WE. Biofeedback therapy for dys-synergic defecation. World J Gastroenterol 2006;12:7069-74.
42. Chiarioni G, Whitehead WE, Pezza V, Morelli A, Bassotti G. Biofeedback is superior to laxatives for normal transit constipation due to pelvic floor dyssynergia. Gastroenterology 2006;130:657-64.
43. Heymen S, Scarlet Y, Jones K, Ringel Y, Drossman D, Whitehead WE. Randomized, controlled trial shows biofeedback to be superior to alternative treatments for patients with pelvic floor dyssynergia-type constipation. Dis Colon Rectum 2007;50:428-41.
44. Rao SS, Seaton K, Miller M, Brown K, Nygaard I, Stumbo P, et al. Randomized controlled trial of biofeedback, sham feedback, and standard therapy for dyssynergic defecation. Clin Gastroenterol Hepatol 2007;5:331-8.
45. Gila A, Gylin M, Gullberg K, Lindberg G. Biofeedback retraining in patients with functional constipation and paradoxical puborectalis contraction: comparison of anal manometry and sphincter electromyg-
raphy for feedback. Dis Colon Rectum 1997;40:889-95.
46. Heymen S, Wexner SD, Vickers D, Nogueras JJ, Weiss EG, Pikarsky AJ. Prospective, randomized trial comparing four biofeedback techniques for patients with constipation. Dis Colon Rectum 1999;42:1388-93.
47. Koutsomanis D, Lennard-Jones JE, Roy AJ, Kamm MA. Controlled randomised trial of visual biofeedback versus muscle training without a visual display for intractable constipation. Gut 1995;37:95-9.
48. Yang DH, Myung SJ, Jung KW, Seo SY, Koh JE, et al. Anorectal function and the effect of biofeedback therapy in ambulatory spinal cord disease patients having constipation. Scand J Gastroenterol 2010;45:1281-8.